Report

Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

Status
Status: Commission completed
Project no.
A09-05
Last updated

Report documents

  1. Executive summary of the final report

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF document, 101 kB, EN, not accessible
  2. Final report

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
  3. Documentation and evaluation on the preliminary report

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF document, 5 MB, not accessible
  4. Executive summary of the preliminary report

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF document, 139 kB, DE, not accessible
  5. Preliminary report

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
  6. Report plan version 1.0

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF document, 136 kB, not accessible
  7. Documentation and appraisal of comments on the preliminary report plan

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF document, 2 MB, not accessible
  8. Preliminary report plan

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF document, 141 kB, DE, not accessible

Press releases

Galantamine and rivastigmine patches: positive influence on cognition possible

But for both the drugs used to treat Alzheimer’s disease, there is also proof of harm

Additional information

Project details

Project no.
A09-05
Commission
Commission awarded on 18.12.2009 by the Federal Joint Committee (GBA).
Report type
Report
Status
Commission completed
Department/Division
Drug Assessment
Topic
Head and nerves

Connected Projects

  1. Report

    Cholinesterase inhibitors in Alzheimer's disease

    Project no.
    A05-19A
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form